Bisoprolol ( DrugBank: Bisoprolol )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
58肥大型心筋症2
67多発性嚢胞腎1
86肺動脈性肺高血圧症2
113筋ジストロフィー2

58. 肥大型心筋症


臨床試験数 : 126 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05569382
(ClinicalTrials.gov)
August 10, 20224/10/2022Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic CardiomyopathyTreatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic CardiomyopathyDrug: Verapamil;Drug: Bisoprolol;Drug: PlaceboMorten Steen Kvistholm JensenBispebjerg Hospital;Rigshospitalet, Denmark;Viborg Regional Hospital;Zealand University Hospital;Odense University Hospital;Gentofte University HospitalRecruiting18 YearsN/AAll140Phase 4Denmark
2EUCTR2021-006953-77-DK
(EUCTR)
11/04/202231/01/2022The effect of Bisoprolol and Verapamil in non-obstructive hypertrophic cardiomyopathyTreatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy - TEMPO II Non-obstructive Hypertrophic cardiomyopathy
MedDRA version: 20.0;Level: PT;Classification code 10007636;Term: Cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders
MedDRA version: 20.0;Classification code 10049813;Term: Non-obstructive cardiomyopathy;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Level: LLT;Classification code 10061029;Term: Cardiomyopathy primary;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Bisoprolol
INN or Proposed INN: BISOPROLOL
Trade Name: Isoptin
INN or Proposed INN: VERAPAMIL HYDROCHLORIDE
Aarhus University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Phase 2Denmark

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-003182-16-GB
(EUCTR)
26/08/200529/07/2005Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs. Polycystic kidney diseaseTrade Name: CARDURA
Product Name: DOXAZOSIN
Trade Name: MONOCOR
Product Name: BISOPROLOL
Trade Name: ZESTRIL
Product Name: LISINOPRIL
Trade Name: ISTIN
Product Name: AMLODIPINE
Trade Name: AMIAS
Product Name: CANDESARTAN
Trade Name: APRINOX
Product Name: BENDROFLUMETHIAZIDE
Addenbrooke's Hospital TrustNULLNot Recruiting Female: yes
Male: yes
42 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01246037
(ClinicalTrials.gov)
February 201118/11/2010Beta-blockers in i-PAHBeta-blocker Therapy in Idiopathic Pulmonary Arterial HypertensionIdiopathic Pulmonary Arterial HypertensionDrug: BisoprololVU University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentActive, not recruiting18 YearsN/ABoth30Phase 1/Phase 2Netherlands
2EUCTR2010-020424-21-NL
(EUCTR)
10/01/201130/08/2010Betablocker Therapy in Pulmonary Arterial HypertensionBetablocker Therapy in Pulmonary Arterial Hypertension Idiopathic pulmonal arterial hypertension
MedDRA version: 12.1;Level: LLT;Classification code 10020787;Term: Hypertension pulmonary
Product Name: Bisoprolol
Product Code: C07AB07
VU medical centerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03779646
(ClinicalTrials.gov)
January 16, 201914/12/2018Bisoprolol in DMD Early CardiomyopathyBisoprolol for Early Cardiomyopathy in Duchenne Muscular Dystrophy: a Randomized, Controlled TrialDuchenne Muscular Dystrophy;Cardiomyopathy, DilatedDrug: Bisoprolol FumaratePeking Union Medical College HospitalNational Natural Science Foundation of China;Chinese Academy of Medical SciencesRecruiting7 YearsN/AMale42Phase 2/Phase 3China
2EUCTR2007-005932-10-GB
(EUCTR)
30/03/200914/04/2009A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart ProtectionA double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction - DMD-Heart Protection Duchenne muscular dystrophy
MedDRA version: 9.1;Level: LLT;Classification code 10013801;Term: Duchenne muscular dystrophy
Trade Name: Perindopril 2mg Tablets
Product Name: Perindopril
Trade Name: Cardicor (Merck brand)
Product Name: Bisoprolol
Newcastle upon Tyne Hospitals NHS Foundation TrustNULLNot Recruiting Female: no
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited Kingdom